Detalles de la búsqueda
1.
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC.
Int J Mol Sci
; 24(17)2023 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37685884
2.
Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition.
Int J Mol Sci
; 21(8)2020 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32325863
3.
MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations.
Transl Lung Cancer Res
; 13(4): 940-946, 2024 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38736494
4.
Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance.
Cancers (Basel)
; 11(7)2019 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31266248
5.
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non-Small-Cell Lung Cancer.
JCO Precis Oncol
; 6: e2200040, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35797511
6.
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Lung Cancer
; 113: 14-17, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29110841
7.
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
BMC Res Notes
; 6: 489, 2013 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-24279718
Resultados
1 -
7
de 7
1
Próxima >
>>